|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Strategies targeting PI3K signal transduction or the association of PI3K with Rb, or regulating PI3K-Rb interactions could be employed for gene therapy or chemotherapy of gastric cancer and other tumors.
|
15809724 |
2005 |
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations were identified in formalin-fixed and paraffin-embedded surgical specimens from 112 patients with EBV-GC with available tumor tissue samples.
|
30952761 |
2019 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mangiferin prevents the growth of gastric carcinoma by blocking the PI3K-Akt signalling pathway.
|
29215373 |
2017 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggested that the PI3K/Akt inhibitor LY294002 can enhance chemosensitivity of human gastric cancer to VCR.
|
23743572 |
2013 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrates, for the first time, that SHIP2 is frequently downregulated in gastric cancer, and reduced SHIP2 expression promotes tumorigenesis and proliferation of gastric cancer via activation of the PI3K/Akt signaling.
|
26201869 |
2016 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.
|
25701378 |
2015 |
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Additionally, we reviewed the rate of PIK3CA mutations in gastric cancer and the association between PIK3CA mutations and prognosis in human cancers.
|
27388016 |
2016 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that LMO4 promotes GC cell invasion and proliferation mainly through PI3K-Akt-mTOR signaling.
|
31737204 |
2019 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway.
|
29282102 |
2017 |
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No relationship was found between PIK3CA mutations and clinicopathological characteristics and clinical outcome in gastric cancer.
|
22292935 |
2012 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Wnt/β-catenin and PI3K/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation.
|
28671020 |
2017 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The experimental methods are as follows: (1) The proliferation of HGC-27 cells inhibited by Apatinib and LY294002 was observed by 3-(4,5)-dimethylthiahiazo-(z-y1)-3,5-diphenytetrazoli- umromide (MTT) assay; (2) flow cytometry was adopted to detect the apoptosis of cells after they were treated with drugs and the positive control; (3) different effects of varying concentrations of Apatinib on apoptosis-related genes and proteins, B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax) and cysteine-aspartic acid protease (Caspase) 9, were detected via fluorescence quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blotting (WB), and the effects of different concentrations of Apatinib on the protein expressions of PI3K, phosphorylated (p)-PI3K, Akt and p-Akt were detected by Western blotting.
|
31786865 |
2020 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, MGr1-Ag/37LRP may interact with PrP<sup>C</sup> and promote the PrP<sup>C</sup> induced multi-drug-resistance in gastric cancer through PI3K/AKT pathway.
|
29069734 |
2017 |
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Are PIK3CA Mutation and Amplification Associated with Clinicopathological Characteristics of Gastric Cancer?
|
26107192 |
2015 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to investigate the effects of combined treatment with Notch1 signaling blocker DAPT and PI3K/Akt signal blocker LY294002 on metastasis of gastric cancer.
|
31732769 |
2020 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study consolidates knowledge on the frequency, co-occurrence and clinical relevance of PI3K pathway aberrations in GC and CRC.
|
23960014 |
2014 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our results suggest that PrP(C)-induced MDR in gastric cancer is associated with activation of the PI3K/Akt pathway.
|
19143835 |
2009 |
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the present study, the status of KRAS, BRAF and PIK3CA mutations in gastric cancer were investigated concomitantly in order to aid the selection of patients eligible for treatment with cetuximab.
|
25815786 |
2015 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PIK3R3, the gene that encodes the PI3K regulatory subunit p55γ, is over-expressed in glioblastoma and ovarian cancers, but its expression in gastric cancer (GC) is not known.
|
22876838 |
2012 |
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Everolimus monotherapy was satisfactory in a patient with refractory metastatic GC harboring PIK3CA and pS6 aberrations.
|
25886409 |
2015 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA PICART1 inhibits cell proliferation by regulating the PI3K/AKT and MAPK/ERK signaling pathways in gastric cancer.
|
30720166 |
2019 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these data suggest that the combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib may be a promising therapeutic regimen for the treatment of gastric cancer, and ARID1A deficiency could serve as a potential predictive therapeutic biomarker.
|
29767248 |
2018 |
|
Stomach Carcinoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
These results show that H. pylori infection induces AKT/PI3K-mediated phosphorylation of p27 at T157 and T198 to cause cytoplasmic p27 mislocalization in gastric cancer, and that p27 mislocalization is an adverse prognostic feature in gastric cancer.
|
21841827 |
2012 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The cooperation between RUNX3 and the PI3K/Akt signaling pathway component FoxO3a/FKHRL1 suggests the putative role of RUNX3 in the homoeostasis of gastric cells and in stomach cancer control.
|
16627973 |
2006 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggested that CSNK2A1 plays important oncogenic roles in GC invasion via EMT and the PI3K-Akt-mTOR signaling pathway and that CSNK2A1 may serve as a novel prognostic and/or therapeutic target in GC.
|
31819646 |
2019 |